RxDoctor Payments DataLook up a doctor →

Christina Kennelly, MD

Internal Medicine · Charlotte, NCNPI 1720214281

Payments from drug & device makers

$15,367,676in general payments, 2019–2025

Across 3,336 payments — averaging $4606.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$9.5M
  • Janssen Research & Development, LLC$3.4M
  • Boehringer Ingelheim$1.2M
  • Pfizer$741K
  • Eli Lilly$180K
  • Alnylam Pharmaceuticals Inc.$85K
  • plus $270K from 31 others

What the payments were for

  • Travel & lodging$372%
  • Food & beverage$2,40898%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$15,367,676 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$175,772
Medicare patients
395
Services billed
3,704

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide50$48,672
EliquisApixaban38$37,108
OzempicSemaglutide38$34,846
FarxigaDapagliflozin Propanediol21$20,093
XareltoRivaroxaban13$19,954
TrulicityDulaglutide13$10,910
JanuviaSitagliptin Phosphate17$9,272
SynthroidLevothyroxine Sodium83$8,780
PaxlovidNirmatrelvir/Ritonavir26$5,656
Rosuvastatin Calcium415$4,262
Estradiol69$3,694
Atorvastatin Calcium320$3,015
Levothyroxine Sodium333$2,976
Omeprazole196$2,960
Duloxetine Hcl77$2,495

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$78$59,58263 claims
PfizerEliquis, Paxlovid$740,953$42,76464 claims
Novo NordiskOzempic$379$34,84638 claims
AstraZenecaFarxiga$35,374$20,09321 claims
Johnson & JohnsonXarelto$12$19,95413 claims
MerckJanuvia$10,500$9,27217 claims
AbbVieSynthroid$578$8,78083 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$19$2,976333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →